DENDRITIC CELL FUNCTIONALITY IS MODULATED BY TOXOPLASMA GONDII SERINE PROTEASE INHIBITOR-1 (TgPI-1).

A SOTO, A FARIAS, M PERRONE SIBILIA, ALDIRÍCO MA, P BERGUER, V MARTIN, I FENOY, A GOLDMAN

Otro; LXVII Reunión Anual de la Sociedad Argentina de Inmunología; 2019

We previously showed that treatment with a recombinant T. gondii serine protease inhibitor-1 (rTgPI-1) significantly reduced experimental asthma. Co-administration of rTgPI-1 with the allergen showed an improvement compared with the administration of rTgPI-1 alone, suggesting that this inhibitor may function as a tolerogenic adjuvant. To further study the mechanism behind TgPI-1 immunomodulatory activity, we aimed to study the effect of this protease inhibitor on dendritic cells (DCs). Murine DCs were obtained from BALB/c mice bone-marrow precursors, cultured for nine days with GM-CSF and then stimulated with LPS. rTgPI-1 (depleted from endotoxin) was added following three different protocols: rTgPI-1 was added a) during differentiation (day 3-9), b) to immature DCs or c) to DCs matured with LPS. A diminished percentage of CD11+MHCII+ DCs were obtained when rTgPI-1 was added during differentiation (p